The diagnostic and therapeutic approach to the axilla in breast cancer patients has changed significantly over the past 30 years, with the replacement of complete axillary lymph node dissection practices by less invasive approaches. Reference is made to clinical findings that have led to practical treatment recommendations and are paving the way to new levels of de-escalation in breast cancer surgery.
ToomeyALewisCR. Axillary lymphadenectomy. In: StatPearls [Internet]. Treasure Island, FL: StatPearls Publishing; 2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK557873/
2.
NomikosIN. Breast cancer and axillary lymph node dissection: past, present, future. Hellenic J Surg. 2018;90:167-168. doi:10.1007/s13126-018-0465-z
3.
GoldhirschAGlickJHGelberRDSennHJ. Meeting highlights: international consensus panel on the treatment of primary breast cancer. J Natl Cancer Inst. 1998;90:1601-1608. doi:10.1093/jnci/90.21.1601
4.
Van de VijverMJHeYDvan’t VeerLJ, et al.A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002;347:1999-2009. doi:10.1056/NEJMoa021967
5.
RescignoJZampellJCAxelrodD. Patterns of axillary surgical care for breast cancer in the era of sentinel lymph node biopsy. Surg Oncol. 2009;16:687-696. doi:10.1245/s10434-008-0195-5
6.
AmersiFGiulianoAE. Management of the axilla. Hematol Oncol Clin North Am. 2013;27:687-702. doi:10.1016/j.hoc.2013.05.002
7.
BembenekASchlagPM. Sentinel node detection. In: HolzheimerRGMannickJA, eds. Surgical Treatment: Evidence-Based and Problem-Oriented. Munich: Zuckschwerdt; 2001. Available from: https://www.ncbi.nlm.nih.gov/books/NBK6977/
8.
KragDNWeaverDLAlexJCFairbankJT. Surgical resection and radiolocalization of the sentinel lymph node in breast cancer using a gamma probe. Surg Oncol. 1993;2:335-339. doi:10.1016/0960-7404(93)90064-6
9.
HuntKKBallmanKVMcCallLM, et al.Factors associated with local-regional recurrence after a negative sentinel node dissection: results of the ACOSOG Z0010 trial. Ann Surg. 2012;256:428-436. doi:10.1097/SLA.0b013e3182654494
10.
FisherCSMargenthalerJAHuntKKSchwartzT. The landmark series: axillary management in breast cancer. Ann Surg Oncol. 2020;27:724-729. doi:10.1245/s10434-019-08154-5
11.
KragDNAndersonSJJulianTB, et al.Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol. 2010;11:927-933. doi:10.1016/S1470-2045(10)70207-2
12.
ManselREFallowfieldLKissinM, et al.Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC trial. J Natl Cancer Inst. 2006;98:599-609. doi:10.1093/jnci/djj158
13.
GalimbertiVColeBFZurridaS, et al.Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. Lancet Oncol. 2013;14:297-305. doi:10.1016/S1470-2045(13)70035-4
14.
McCartanDGemignaniML. Current management of the axilla. Clin Obstet Gynecol. 2016;59:743-755. doi:10.1097/GRF.0000000000000232
15.
FisherBWolmarkNRedmondCDeutschMFisherER. Findings from NSABP Protocol No. B-04: comparison of radical mastectomy with alternative treatments. II. The clinical and biologic significance of medial-central breast cancers. Cancer. 1981;48:1863-1872. doi:10.1002/1097-0142(19811015)48:8<1863::aid-cncr2820480825>3.0.co;2-u
16.
FisherBMontagueERedmondC, et al.Findings from NSABP Protocol No. B-04-comparison of radical mastectomy with alternative treatments for primary breast cancer. I. Radiation compliance and its relation to treatment outcome. Cancer. 1980;46:1-13. doi:10.1002/1097-0142(19800701)46:1<1::aid-cncr2820460102>3.0.co;2-3
17.
GiulianoAEBallmanK V.McCallL, et al.Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) randomized clinical trial. JAMA - Journal of the American Medical Association. 2017;318:918-926. doi:10.1001/jama.2017.11470
18.
GiulianoAEMcCallLBeitschP, et al.Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg. 2010;252:426-432. doi:10.1097/SLA.0b013e3181f08f32
19.
DengelLTVan ZeeKJKingTA, et al.Axillary dissection can be avoided in the majority of clinically node-negative patients undergoing breast-conserving therapy. Ann Surg Oncol. 2014;21:22-27. doi:10.1245/s10434-013-3200-6
20.
YiMKuererHMMittendorfEA, et al.Impact of the American College of Surgeons Oncology Group Z0011 criteria applied to a contemporary patient population. J Am Coll Surg. 2013;216:105-113. doi:10.1016/j.jamcollsurg.2012.09.005
21.
RobertsANofech-MozesSYoungsonB, et al.The importance of applying ACOSOG Z0011 criteria in the axillary management of invasive lobular carcinoma: a multi-institutional cohort study. Ann Surg Oncol. 2015;22:3397-3401. doi:10.1245/s10434-015-4756-0
22.
DonkerMvan TienhovenGStraverME, et al.Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol. 2014;15:1303-1310. doi:10.1016/S1470-2045(14)70460-7
23.
SávoltÁPéleyGPolgárC, et al.Eight-year follow-up result of the OTOASOR trial: the optimal treatment of the axilla - surgery or radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: a randomized, single centre, phase III, non-inferiority trial. Eur J Surg Oncol. 2017;43:672-679. doi:10.1016/j.ejso.2016.12.011
24.
BougheyJCSumanVJMittendorfEA, et al.Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (alliance) clinical trial. JAMA. 2013;310:1455-1461. doi:10.1001/jama.2013.278932
25.
KuehnTBauerfeindIFehmT, et al.Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol. 2013;14:609-618. doi:10.1016/S1470-2045(13)70166-9
26.
GiulianoAEKirganDMGuentherJMMortonDL. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg. 1994;220:391-398. doi:10.1097/00000658-199409000-00015
27.
TafraLLanninDRSwansonMS, et al.Multicenter trial of sentinel node biopsy for breast cancer using both technetium sulfur colloid and isosulfan blue dye. Ann Surg. 2001;233:51-59. doi:10.1097/00000658-200101000-00009
28.
McMastersKMTuttleTMCarlsonDJ, et al.Sentinel lymph node biopsy for breast cancer: a suitable alternative to routine axillary dissection in multi-institutional practice when optimal technique is used. J Clin Oncol. 2000;18:2560-2566. doi:10.1200/JCO.2000.18.13.2560
29.
KimTGiulianoAELymanGH. Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: a meta-analysis. Cancer. 2006;106:4-16. doi:10.1002/cncr.21568
30.
ZavagnoGDe SalvoGLScalcoG, et al.A randomized clinical trial on sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer: results of the Sentinella/GIVOM trial. Ann Surg. 2008;247:207-213. doi:10.1097/SLA.0b013e31812e6a73
31.
KuruBGulcelikMATopgulK, et al.Application of sentinel node biopsy in breast cancer patients with clinically negative and positive axilla and role of axillary ultrasound examination to select patients for sentinel node biopsy. J BUON. 2011;16:454-459.
32.
MatsenCVillegasKEatonA, et al.Late axillary recurrence after negative sentinel lymph node biopsy is uncommon. Ann Surg Oncol. 2016;23:2456-2461.
33.
van der PloegIMCNiewegOEvan RijkMCValdés OlmosRAKroonBBR. Axillary recurrence after a tumour-negative sentinel node biopsy in breast cancer patients: a systematic review and meta-analysis of the literature. Eur J Surg Oncol. 2008;34:1277-1284. doi:10.1016/j.ejso.2008.01.034
34.
VeronesiUVialeGPaganelliG, et al.Sentinel lymph node biopsy in breast cancer: ten-year results of a randomized controlled study. Ann Surg. 2010;251:595-600. doi:10.1097/SLA.0b013e3181c0e92a
35.
LymanGHGiulianoAESomerfieldMR, et al.American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol. 2005;23:7703-7720. doi:10.1200/JCO.2005.08.001
36.
OzaslanCKuruB. Lymphedema after treatment of breast cancer. Am J Surg. 2004;187:69-72. doi:10.1016/j.amjsurg.2002.12.003
37.
ArmerJMBallmanK VMcCallL, et al.Factors associated with lymphedema in women with node-positive breast cancer treated with neoadjuvant chemotherapy and axillary dissection. JAMA Surg. 2019;154:800-809. doi:10.1001/jamasurg.2019.1742
38.
KuruB. The adventure of axillary treatment in early-stage breast cancer. Eur J Breast Health. 2020;16:1-15. doi:10.5152/ejbh.2019.5157
39.
DiepstratenSCESeverARBuckensCFM, et al.Value of preoperative ultrasound-guided axillary lymph node biopsy for preventing completion axillary lymph node dissection in breast cancer: a systematic review and meta-analysis. Ann Surg Oncol. 2014;21:51-59. doi:10.1245/s10434-013-3229-6
40.
PilewskieMJochelsonMGoochJCPatilSStempelMMorrowM. Is preoperative axillary imaging beneficial in identifying clinically node-negative patients requiring axillary lymph node dissection?J Am Coll Surg. 2016;222:138-145. doi:10.1016/j.jamcollsurg.2015.11.013
41.
BartelsSALDonkerMPoncetC, et al.Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer: 10-year results of the randomized controlled EORTC 10981-22023 AMAROS trial. J Clin Oncol. 2023;41(12):2159-2165. doi:10.1200/JCO.22.01565
42.
BhimaniFardeenMcEvoyMaureenChenYu, et al.Comprehensive strategies in breast cancer-related lymphedema prevention: insights from a multifaceted program. Front Oncol. 2024;14:1418610. doi:10.3389/fonc.2024.1418610
43.
OzmenT.LazaroM.ZhouY.VinyardA.AvisarE. Evaluation of simplified lymphatic microsurgical preventing healing approach (S-LYMPHA) for the prevention of breast cancer-related clinical lymphedema after axillary lymph node dissection. Ann Surg. 2019;270(6):1156-1160. doi:10.1097/SLA.0000000000002827
44.
McEvoyMPRavetchEPatelGFoxJFeldmanS. Prevention of breast cancer-related lymphedema. Clin Breast Cancer. 2021;21:128-142. doi:10.1016/j.clbc.2021.02.009
45.
GradisharWJMoranMSAbrahamJ, et al.NCCN Guidelines® insights: breast cancer, version 4.2023. J Natl Compr Canc Netw. 2023;21:594-608. doi:10.6004/jnccn.2023.0031
46.
NguyenTTHoskinTLDayCN, et al.Decreasing use of axillary dissection in node-positive breast cancer patients treated with neoadjuvant chemotherapy. Ann Surg Oncol. 2018;25:2596-2602. doi:10.1245/s10434-018-6637-9
47.
CuriglianoGBursteinHJWinerEP, et al.De-escalating and escalating treatments for early-stage breast cancer: the st. Gallen international expert consensus conference on the primary therapy of early breast cancer 2017. Annals of Oncology. 2017;28:1700-1712. doi:10.1093/annonc/mdx308
48.
GradisharWJMoranMSAbrahamJ, et al.Breast cancer, version 3.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022;20:691-722. doi:10.6004/jnccn.2022.0030
49.
KuemmelSHeilJRuelandA, et al.A prospective, multicenter registry study to evaluate the clinical feasibility of targeted axillary dissection (TAD) in node-positive breast cancer patients. Ann Surg. 2022;276:553-562. doi:10.1097/SLA.0000000000004572
50.
SwarnkarPKTayehSMichellMJMokbelK. The evolving role of Marked Lymph Node Biopsy (MLNB) and Targeted Axillary Dissection (TAD) after Neoadjuvant Chemotherapy (NACT) for node-positive breast cancer: systematic review and pooled analysis. Cancers (Basel). 2021;13:1539.
51.
CaudleASKuererHM. Targeting and limiting surgery for patients with node-positive breast cancer. BMC Med. 2015;13:149. doi:10.1186/s12916-015-0385-5
52.
CaudleASYangWTKrishnamurthyS, et al.Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection. J Clin Oncol. 2016;34:1072-1078. doi:10.1200/JCO.2015.64.0094
53.
DonkerMStraverMEWesselingJ, et al.Marking axillary lymph nodes with radioactive iodine seeds for axillary staging after neoadjuvant systemic treatment in breast cancer patients the mari procedure. Ann Surg. 2015;261:378-382. doi:10.1097/SLA.0000000000000558
54.
Flores-FunesDAguilar-JiménezJMartínez-GálvezM, et al.Validation of the targeted axillary dissection technique in the axillary staging of breast cancer after neoadjuvant therapy: preliminary results. Surg Oncol. 2019;30:52-57. doi:10.1016/j.suronc.2019.05.019
55.
CaudleASYangWTMittendorfEA, et al.Selective surgical localization of axillary lymph nodes containing metastases in patients with breast cancer: a prospective feasibility trial. JAMA Surg. 2015;150:137-143. doi:10.1001/jamasurg.2014.1086
56.
MacedoFIBEidJJFlynnJJacobsMJMittalVK. Optimal surgical management for occult breast carcinoma: a meta-analysis. Ann Surg Oncol. 2016;23:1838-1844. doi:10.1245/s10434-016-5104-8
57.
HughesKSSchnaperLABellonJR, et al.Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol. 2013;31:2382-2387. doi:10.1200/JCO.2012.45.2615
58.
MartelliGMiceliRDaidoneMG, et al.Axillary dissection versus no axillary dissection in elderly patients with breast cancer and no palpable axillary nodes: results after 15 years of follow-up. Ann Surg Oncol. 2011;18:125-133. doi:10.1245/s10434-010-1217-7
59.
International Breast Cancer Study GroupRudenstamCMZahriehD, et al.Randomized trial comparing axillary clearance versus no axillary clearance in older patients with breast cancer: first results of International Breast Cancer Study Group Trial 10-93. J Clin Oncol. 2006;24:337-344. doi:10.1200/JCO.2005.01.5784
60.
BredbeckBCBaskinASWangT, et al.Incremental spending associated with low-value treatments in older women with breast cancer. Ann Surg Oncol. 2022;29:1051-1059. doi:10.1245/s10434-021-10807-3
61.
OresteDGEdoardoBSangalliC, et al.Sentinel lymph node biopsy vs no axillary surgery in patients with small breast cancer and negative results on ultrasonography of axillary lymph nodes the SOUND randomized clinical trial. JAMA Oncol. 2023;9(11):1557-1564. doi:10.1001/jamaoncol.2023.3759
62.
ReimerT.StachsA.VeselinovicK.INSEMA investigators. Patient-reported outcomes for the Intergroup Sentinel Mamma study (INSEMA): a randomised trial with persistent impact of axillary surgery on arm and breast symptoms in patients with early breast cancer. EClinicalMedicine. 2023;55:101756. doi:10.1016/j.eclinm.2022.101756
